Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States

BACKGROUND: There are limited data on economic aspects of the genetic variant of chronic obstructive pulmonary disease (COPD) in the context of the more prevalent form of COPD. The objective of this study was to isolate the healthcare resource utilization and economic burden attributable to the pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Sieluk, Jan, Slejko, Julia F., Silverman, Henry, Perfetto, Eleanor, Mullins, C. Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510284/
https://www.ncbi.nlm.nih.gov/pubmed/32967697
http://dx.doi.org/10.1186/s13023-020-01523-4
_version_ 1783585755696726016
author Sieluk, Jan
Slejko, Julia F.
Silverman, Henry
Perfetto, Eleanor
Mullins, C. Daniel
author_facet Sieluk, Jan
Slejko, Julia F.
Silverman, Henry
Perfetto, Eleanor
Mullins, C. Daniel
author_sort Sieluk, Jan
collection PubMed
description BACKGROUND: There are limited data on economic aspects of the genetic variant of chronic obstructive pulmonary disease (COPD) in the context of the more prevalent form of COPD. The objective of this study was to isolate the healthcare resource utilization and economic burden attributable to the presence of a genetic factor among COPD patients with and without Alpha-1 Antitrypsin Deficiency (AATD), twelve months before and after their initial COPD diagnosis. METHODS: Retrospective analysis of OptumLabs® Data Warehouse claims (OLDW; 2000–2017). The OLDW is a comprehensive, longitudinal real-world data asset with de-identified lives across claims and clinical information. AATD-associated COPD cases were matched with up to 10 unique non-AATD-associated COPD controls. Healthcare resource use and costs were assigned into the following categories: office (OV), outpatient (OP), and emergency room visits (ER), inpatients stays (IP), prescription drugs (RX), and other services (OTH). A generalized linear model was used to estimate total pre- and post-index (initial COPD diagnosis) costs from a third-party payer’s perspective (2018 USD) controlling for confounders. Healthcare resource utilization was estimated using a negative binomial regression. RESULTS: The study population consisted of 8881 patients (953 cases matched with 7928 controls). The AATD-associated COPD cohort had higher expenditures and use of office visits (OV) and other (OTH) services, as well as OV, outpatient (OP), emergency room (ER), and prescription drugs (RX) before and after the index date, respectively. Adjusted total all-healthcare cost ratios for AATD-associated COPD patients as compared to controls were 2.04 [95% CI: 1.60–2.59] and 1.98 [95% CI: 1.55–2.52] while the incremental cost difference totaled $6861 [95% CI: $3025 - $10,698] and $5772 [95% CI: $1940 - $9604] per patient before and after the index date, respectively. CONCLUSIONS: Twelve months before and after their initial COPD diagnosis, patients with AATD incur higher healthcare utilization costs that are double the cost of similar COPD patients without AATD. This study also suggests that increased costs of AATD-associated COPD are not solely attributable to augmentation therapy use. Future studies should further explore the relationship between augmentation therapy, healthcare resource use, and other AATD-associated COPD expenditures.
format Online
Article
Text
id pubmed-7510284
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75102842020-09-25 Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States Sieluk, Jan Slejko, Julia F. Silverman, Henry Perfetto, Eleanor Mullins, C. Daniel Orphanet J Rare Dis Research BACKGROUND: There are limited data on economic aspects of the genetic variant of chronic obstructive pulmonary disease (COPD) in the context of the more prevalent form of COPD. The objective of this study was to isolate the healthcare resource utilization and economic burden attributable to the presence of a genetic factor among COPD patients with and without Alpha-1 Antitrypsin Deficiency (AATD), twelve months before and after their initial COPD diagnosis. METHODS: Retrospective analysis of OptumLabs® Data Warehouse claims (OLDW; 2000–2017). The OLDW is a comprehensive, longitudinal real-world data asset with de-identified lives across claims and clinical information. AATD-associated COPD cases were matched with up to 10 unique non-AATD-associated COPD controls. Healthcare resource use and costs were assigned into the following categories: office (OV), outpatient (OP), and emergency room visits (ER), inpatients stays (IP), prescription drugs (RX), and other services (OTH). A generalized linear model was used to estimate total pre- and post-index (initial COPD diagnosis) costs from a third-party payer’s perspective (2018 USD) controlling for confounders. Healthcare resource utilization was estimated using a negative binomial regression. RESULTS: The study population consisted of 8881 patients (953 cases matched with 7928 controls). The AATD-associated COPD cohort had higher expenditures and use of office visits (OV) and other (OTH) services, as well as OV, outpatient (OP), emergency room (ER), and prescription drugs (RX) before and after the index date, respectively. Adjusted total all-healthcare cost ratios for AATD-associated COPD patients as compared to controls were 2.04 [95% CI: 1.60–2.59] and 1.98 [95% CI: 1.55–2.52] while the incremental cost difference totaled $6861 [95% CI: $3025 - $10,698] and $5772 [95% CI: $1940 - $9604] per patient before and after the index date, respectively. CONCLUSIONS: Twelve months before and after their initial COPD diagnosis, patients with AATD incur higher healthcare utilization costs that are double the cost of similar COPD patients without AATD. This study also suggests that increased costs of AATD-associated COPD are not solely attributable to augmentation therapy use. Future studies should further explore the relationship between augmentation therapy, healthcare resource use, and other AATD-associated COPD expenditures. BioMed Central 2020-09-23 /pmc/articles/PMC7510284/ /pubmed/32967697 http://dx.doi.org/10.1186/s13023-020-01523-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sieluk, Jan
Slejko, Julia F.
Silverman, Henry
Perfetto, Eleanor
Mullins, C. Daniel
Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States
title Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States
title_full Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States
title_fullStr Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States
title_full_unstemmed Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States
title_short Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States
title_sort medical costs of alpha-1 antitrypsin deficiency-associated copd in the united states
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510284/
https://www.ncbi.nlm.nih.gov/pubmed/32967697
http://dx.doi.org/10.1186/s13023-020-01523-4
work_keys_str_mv AT sielukjan medicalcostsofalpha1antitrypsindeficiencyassociatedcopdintheunitedstates
AT slejkojuliaf medicalcostsofalpha1antitrypsindeficiencyassociatedcopdintheunitedstates
AT silvermanhenry medicalcostsofalpha1antitrypsindeficiencyassociatedcopdintheunitedstates
AT perfettoeleanor medicalcostsofalpha1antitrypsindeficiencyassociatedcopdintheunitedstates
AT mullinscdaniel medicalcostsofalpha1antitrypsindeficiencyassociatedcopdintheunitedstates